Status:
TERMINATED
A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.
Lead Sponsor:
Pfizer
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the long-term safety and tolerability of \[S,S\]-Reboxetine in patients with chronic pain following shingles. This is the extension study of Protocol A6061026.
Eligibility Criteria
Inclusion
- Patients must have met the patient selection criteria for the preceding double-blind Protocol A6061026 and have completed the 16-week trial.
- Patients at screening must have a score of \>/=40mm on the pain visual analogue scale.
Exclusion
- Serious adverse event during the preceding double-blind Protocol A6061026 that was determined to be related to the trial medication by the Investigator.
- Patient treatment compliance was less than 80% in the preceding double-blind Protocol A6061026.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00353808
Start Date
July 1 2006
End Date
October 1 2007
Last Update
April 7 2011
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
2
Pfizer Investigational Site
Chandler, Arizona, United States, 85225
3
Pfizer Investigational Site
Gilbert, Arizona, United States, 85234
4
Pfizer Investigational Site
Sun City, Arizona, United States, 85351